Serving over 1000 clients worldwide Supported solid form screening, crystallization, and preclinical formulation development of over 2,000 new dr
Mol2Med™ First-Time-Right 3-STEP ApproachCrystal Pharmatech are a specialized CRO/CDMO focused on Solid State Research, Pre-Formulation, contra
A comprehensive physicochemical property evaluation is an important premise for the development of formulation and process. It provides an important b
Contrary to popular belief, early formulation development is not simply dumping API in a vehicle and gavage feeding an animal. If you do this, you wil
Nanocrystal drugs are characterized by particle sizes in the nanometer range, typically below 1 μm (practically ranging from 200 to 500 nm). Formulations utilizing nanocrystals exhibit very small particle sizes, offering distinctive properties and benefits. These include heightened drug solubility, expanded surface area, improved bioavailability, and accelerated drug release.
We perform comprehensive amorphous solid dispersion screening to identify ASD formulation that can provide sufficient solubility and drug release rate. Our capabilities include making mg quantity material for early development up to kilogram scale for late-stage studies to support different needs.
We perform comprehensive amorphous solid dispersion screening to identify ASD formulation that can provide sufficient solubility and drug release rate. Our capabilities include making mg quantity material for early development up to kilogram scale for late-stage studies to support different needs.
We perform comprehensive amorphous solid dispersion screening to identify ASD formulation that can provide sufficient solubility and drug release rate. Our capabilities include making mg quantity material for early development up to kilogram scale for late-stage studies to support different needs.